High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
1 clinical trials · Condition
◉ Watch High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
| Record | Firm | Date |
|---|---|---|
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer (NCT06555796) | Amgen | 2024-09-23 |
Track High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer automatically
Every clearance here is in the API, with alerts when new ones post.